about
Major issues and challenges of influenza pandemic preparedness in developing countriesCurrent and future antiviral therapy of severe seasonal and avian influenzaEmerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?An assay suitable for high throughput screening of anti-influenza drugsDevelopment and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparednessPandemic influenza planning in nursing homes: are we prepared?Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data.Vaccines for pandemic influenzaNeuraminidase inhibitor resistance in influenza viruses.Prioritization strategies for pandemic influenza vaccine in 27 countries of the European Union and the Global Health Security Action Group: a reviewScenarios of diffusion and control of an influenza pandemic in Italy.Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenariosDeaths from bacterial pneumonia during 1918-19 influenza pandemic.Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virusDetection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birdsANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.Vaccination against influenza: role and limitations in pandemic intervention plans.Evidence-based medicine and the governance of pandemic influenza.Do the omeprazole family compounds exert a protective effect against influenza-like illness?Resource allocation for epidemic control in metapopulations.Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterasesImportance of collection tube during clinical studies of oseltamivir.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA.A slippery disease: a microbiologist's viewA novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase.Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome.The threat of avian influenza A (H5N1). Part III: Antiviral therapy.An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.Virtual epidemic in a virtual city: simulating the spread of influenza in a US metropolitan areaAnimal models in virus research: their utility and limitations.A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication.Evaluation of immunogenicity of the 2008-2009 seasonal influenza vaccines by microneutralization test.Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.Awareness of avian influenza ("bird flu") among attendees of a primary healthcare clinic in Riyadh.Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach.Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: in vivo assessment of 3'-sialyllactose against H9N2 in chickens.
P2860
Q24646958-066B15D8-7CF9-42E2-9DCF-1DECA80B6944Q24656164-A19AF5F2-7CFB-469C-8E83-CB583D87F1FFQ26783481-96D5E5F5-35D8-484F-8302-CD442A0046BFQ28484953-6FAF2DA9-3598-4256-8037-5CE2EFB01EE3Q30229346-E0B12492-0546-405F-BEE5-F44B0FE46EF5Q30229411-0DF3EB54-A4E7-4F89-9D45-B84B95F9DE6CQ30250234-FD642CCA-D777-4FA8-8DB8-08D2A740447CQ30353073-B6DD0F3D-3EB3-4DE6-AD0D-AA904DCC3D96Q30363488-354C1735-5FDA-42C4-BDEA-DC52206FF9FCQ30364348-7BEA57DB-5477-42F8-8A2F-37B42DA7D466Q30367736-FE65A9EB-A725-48B2-8683-693B900F8DD6Q30368195-A9227B34-DAE3-40B4-9C44-E0112CC818FBQ30371219-7DDB827E-3E20-4A05-AA08-43325E539D1DQ30386212-15C6A3B8-9E40-4F73-ADA2-C50A5CB01463Q30391443-236AD8A1-046F-4E52-9768-0D4914EC46B5Q30398804-4C1A685A-5042-4184-AEA9-0AB43498D98FQ30404586-081AA4E7-41FA-4163-8385-F373457F38E1Q30420990-F1D81A5C-0AD1-4871-A705-22AE39D7106DQ30421562-BD7001D3-D3B3-476D-BD31-E116AA4C83DCQ30421871-FD6F6ED0-263C-4A8A-B3EE-32ADDD1B0F6DQ33732181-0B5D25C2-80CA-4320-9F5F-8B1C3B2F0B86Q34023709-91174105-029F-4742-9AAF-00664EE190C0Q35023358-9C1752AA-099A-408F-BAE5-60B62967F79AQ35759115-5ED929E7-F72F-4A9C-9751-0FE9B7F3BB0AQ35826733-E18F7863-9000-43AB-AB92-C26778924308Q36100040-4728CBD2-A7A4-4909-9782-2AF67181D29BQ36436443-3584CDDF-5066-4526-B832-11AFF4787C42Q36666497-2B0F9CC2-E607-4D89-B157-6C501DAB7828Q36754908-00CC9444-0065-469A-B95E-31B9E588D19EQ36790658-AC26625B-965F-4E76-B0E2-4AA687648E5BQ37124744-2EE31463-404C-4E5A-82E1-E31DE53839F3Q37366337-754A877F-31C7-4CFB-A144-C3444A5732DFQ38043556-C3A627BA-673F-40BA-8173-16F494063ABDQ38766044-8B85CE72-ED26-40DD-8141-4AFA09DA5D38Q41881421-A9B1AC16-23F3-4D71-9C02-CF691BB1A96DQ42581818-CC523672-9125-457D-B3F5-A7FAB50BF242Q43176726-6069EBC2-D261-49BE-8AA0-3CFB9FDDBA67Q45353103-BC2C1D7D-BCD1-43C1-BBCE-770B1FB6BFD4Q45403802-C7F2932C-7B29-44C7-B87C-34885B5917E6Q50129876-252551F6-A9F6-456C-9469-A466659A42A9
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vaccines and antiviral drugs in pandemic preparedness
@ast
Vaccines and antiviral drugs in pandemic preparedness
@en
Vaccines and antiviral drugs in pandemic preparedness
@en-gb
Vaccines and antiviral drugs in pandemic preparedness
@nl
type
label
Vaccines and antiviral drugs in pandemic preparedness
@ast
Vaccines and antiviral drugs in pandemic preparedness
@en
Vaccines and antiviral drugs in pandemic preparedness
@en-gb
Vaccines and antiviral drugs in pandemic preparedness
@nl
prefLabel
Vaccines and antiviral drugs in pandemic preparedness
@ast
Vaccines and antiviral drugs in pandemic preparedness
@en
Vaccines and antiviral drugs in pandemic preparedness
@en-gb
Vaccines and antiviral drugs in pandemic preparedness
@nl
P2860
P921
P3181
P356
P1476
Vaccines and antiviral drugs in pandemic preparedness
@en
P2860
P3181
P356
10.3201/EID1201.051068
P407
P577
2006-01-01T00:00:00Z